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Introduction
Since Urist1) demonstrated ectopic bone and carti-
lage formation after the intramuscular implantation of 
demineralized bone matrix in rats, which were later 
named as bone morphogenetic proteins(BMPs), several 
BMPs have been shown to have significant os-
teoinductive activity2-8). It was reported that rhBMP 
itself is sufficient to induce bone formation. However, 
the rapid diffusion of the water-soluble protein 
rhBMP from the implant site will reduce its os-
teoinductive effect. Therefore, a carrier system for 
rhBMPs is essential9-12).
The carrier for BMPs should serve as a scaffold for 
bone forming cells while providing space in which 
bone formation can occur, and resist soft tissue com-
pression during the healing period13). For the clinically 
successful use of BMPs, the carrier should also be 
easy to manipulate, sterilize, and fabricate into the 
intended shape. It is also important that the shape 
and volume of newly formed bone be maintained. If 
these requirements of carrier are satisfied, predictable 
bone regeneration is possible with sufficient value to 
the tissue engineering side. There have been many 
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studies on carriers14-17), but no carriers have satisfied 
these requirements perfectly. 
Micro macroporous biphasic calcium phosphate 
(MBCP) consists of an intimate mixture of 40% β
-tricalcium phosphate(β-TCP) and 60% hydrox-
yapatite(HA)18,19). Besides the well-documented osteo-
conductive effect20-22), the osteoinductive effect of the 
MBCP is recommended for use as an alternative or as 
an additive to autogenous bone for orthopedics, trau-
matology, odontology and dental applications23-28). The 
porous structure, low resorption rate, favorable os-
teoconductivity and bioactive properties of MBCP can 
be utilized by rhBMPs carrier. The easy manipulation 
and producing the intended shape, particularly the 
block type, are additional merits of using this 
biomaterial. However, there has been little study on 
its use as a carrier for BMPs29,30).
The subcutaneous tissue of a rat has poorer con-
ditions than the muscle or bony site or the subcuta-
neous tissue of other animals31-34). Therefore, success 
this region can indicate better success in other 
regions.
This study evaluated the ectopic bone formation of 
rhBMP-2 using a MBCP block as a carrier in a rat 
subcutaneous assay model. 
Materials and Methods
1. Animals
40 male Sprague-Dawley rats (weight 250~300g, 
approximately 8 weeks old) were used. Rats were
maintained in plastic cages in a room with a 
12h-day/night cycle and an ambient temperature of 21ﾟC, 
with ad libitum access to water and standard labo-
ratory pellets. Animal selection and management, sur-
gical protocol, and preparation were in accordance 
with the routines approved by the Institutional Animal 
Care and Use Committee, Yonsei Medical Center, 
Seoul, Korea.
2. rhBMP-2 Implant Construction
Disc-shaped MBCP implants (Biomatlante Inc., 
Vigneux de Bretagne, France) (3mm height and 8mm 
diameter) were manufactured (Fig. 1). rhBMP-2(R & D 
Systems Inc., Minneapolis, MN, USA) was recon-
stituted and diluted in a buffer to produce a concen-
tration of 0.025mg/ml. For the rhBMP-2/MBCP im-
plants, MBCP implants were loaded with 0.2ml of the 
rhBMP-2 solutions for one hour before surgery. For 
the MBCP implants alone, MBCP implants were loaded 
with 0.2ml of buffer solutions. 
Figure 1. Block type MBCP implant used in this 
study (3mm in height and 8mm in diameter). 
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3. Surgical Procedures
The animals were anaesthetized by an intramuscular 
injection (5mg/kg body wt.) of a 4:1 solution of ket-
amine hydrochloride (Ketalar®, Yuhan Co., Seoul, 
Korea) and xylazine(Rompun®, Bayer Korea, Seoul, 
Korea). The surgical site was shaved and scrubbed 
with iodine. A vertical incision was made in the skin 
of the back. After flap reflection, a subcutaneous 
pocket was prepared by blunt instrument. Each animal 
received 1 of 2 experimental treatments: MBCP carrier 
control and rhBMP-2/MBCP. The skin was closed and 
sutured with absorbable monofilament suture 
(Monosyn®, Aesculap AG Co. KG, Tuttlingen, Germany).
4. Histologic and Histometric Procedures
The animals were sacrificed by CO2 asphyxiation at 
2 and 8 weeks post-surgery. Block sections were re-
moved and fixed in a 10% neutral buffered formalin 
solution for 10 days. Samples were decalcified by 5% 
formic acid for 14 days and embedded in paraffin. 
Serial sections 7um in thickness were prepared at in-
tervals of 80um, stained with hematoxylin/eosin 
(H-E), and examined using a light microscope. The 
most central sections from each block were selected 
for histologic and histometric evaluation. 
Computer-assisted histometric measurements were 
obtained using an automated image analysis system 
(Image-Pro Plus®, Media Cybernetics, Silver Spring, 
MD, USA) coupled with a video camera on a light mi-
croscope (Olympus BX50, Olympus Optical Co., Tokyo, 
Japan). Sections were examined at magnifications of 
×20 and ×100. Histometric parameters were defined 
as follows. 
z Total augmented area (mm2): the area of im-
planted MBCP zone.
z New bone area (mm2): the area of newly formed 
bone within the total augmented area. 
5. Statistical Analysis 
Histometric recordings from the samples were used 
to calculate means and standard deviations (m±SD). 
For comparisons between the two groups, a paired or 
unpaired t-test was used. The interactions between 
the healing times were examined using two-way anal-
ysis of variance. A p-value ＜0.01 was considered 
significant. 
Results
1. Clinical observation
Wound healing was generally uneventful and there 
were no signs and symptoms of infection or in-
flammation
2. Histological Observations 
1) MBCP control group
At 2 weeks, histological signs of inflammation or 
foreign body reactions were not generally observed. 
MBCP blocks were surrounded by loose connective 
tissue. Macropores of the block were filled with con-
nective tissue. Osteogenic activity could not found 
histologically (Fig. 2-A, C). At 8 weeks post surgery, 
the implanted block was covered with dense and fi-
brous connective tissue. The minimal amount of new 
bone formation was observed adjacent to the margins 
of the block. No significant resorption of the MBCP 
block was observed during the healing time (Fig. 2-B, D).
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2) MBCP/ rhBMP-2 group
At 2 weeks, the macropores in the periphery of the 
block were filled with new bone. Evidence of osteo-
genic activity, such as dense osteoblast-like cell lin-
ing, osteoid and bone apposition along the surface of 
macropores was observed. Macropores in the center 
part were usually filled with loose fibrous connective 
tissue and there was a little bone-forming activity 
(Fig. 3-A, C).
At 8 weeks, the quantity of new bone was greater 
than that observed at 2 weeks, and the specimens 
showed a more advanced stage of remodeling and 
consolidation. Some macropores with fibrous con-
nective tissue could be also found in the central part 
of the block. The newly formed bone consisted of wo-
ven and lamellar bone, and showed cement lines that 
were separated from the more recently deposited bone. 
There was no evidence of cartilage formation (Fig. 
3-B, D). 
Figure 2. Representative photomicrographs of the MBCP control 
group at 2 weeks (A and C) and 8 weeks (B and D) (arrow head: 
defect margin, NB: new bone; H-E stain; original magnification A 
and B ×20, C and D ×100).
Figure 3. Representative photomicrographs of the rhBMP-2/MBCP 
group at 2 weeks (A and C) and 8 weeks (B and D) (arrow head: 
defect margin, arrow: cement lines, NB: new bone; H-E stain; origi-
nal magnification A and B ×20; C and D ×100).
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3. Histometric Analysis
Table 1 and 2 show the results of histometric 
analysis. In the rhBMP-2/MBCP group, the quantity 
of the new bone was greater at 8 weeks than 2 weeks 
(p＜0.01). 
Discussion
The aim of this study was to evaluate the ectopic 
bone formation of rhBMP-2 using a MBCP block as a 
carrier in a rat subcutaneous assay model. Because 
the subcutaneous tissue of rats have poorer conditions 
than muscle or bony site or the subcutaneous tissue of 
other animals, the success in this region can indicate 
better success in other regions. The results were 
evaluated by histological and histometric analysis af-
ter a 2- and 8-week healing interval. 
In a previous study13) using a similar method to this 
study, it was demonstrated that rhBMP-2, when im-
pregnated in an absorbable collagen sponge(ACS) and 
β-TCP, provoked osteoinductive activity in rat sub-
cutaneous tissue at 2 weeks. However, at 8 weeks 
neither ACS nor the newly formed bone observed at 2 
weeks were found in the rhBMP-2/ACS sites, while 
more expanded bone maturation was observed in the 
rhBMP-2/β-TCP sites. This suggests that ACS does 
not have capacity as a carrier for rhBMP-2 in this 
model. The lack of space-maintaining capacity of ACS 
might be one of the major factors responsible for the 
resorption of the newly-formed bone observed in the 
2-week sections after implantation. It was concluded 
that the carrier for the delivery of BMPs should also 
serve as a scaffold for bone forming cells while pro-
viding sufficient space for bone formation to occur. 
Although favorable ectopic bone formation could be 
obtained using β-TCP particles, questions arise as to 
whether clinical applications are possible, because 
there is clinical difficulty in the nature of its partic-
ulate form, in the manipulation and maintenance of 
the intended shape of the bone. Since predictable bone 
tissue regeneration might be one of the major goals of 
the clinical therapeutic results, a carrier system for 
rhBMPs should provide stability over time in terms of 
volume and shape.
MBCP consists of an intimate mixture of 40% β
-TCP and 60% HA, and is obtained when a synthetic 
calcium deficient apatite is sintered at ≥700ﾟC. It is 
now available in blocks, particulates and as an in-
jectable material in a polymer carrier18,19). MBCP has 
excellent biocompatibility and bioactivity, which is re-
lated to its porous structure20-22). Micropores≤10μm 
allow fluid circulation, leading to the dissolution and 
Table 1. Total Augmented Area (group means ±SD, mm2, n=10)
Group 2 weeks 8 weeks
MBCP 21.9 ± 2.6 19.9 ± 2.8
rhBMP-2/MBCP 23.7 ± 1.9 23.5 ± 2.4
  No significant difference when compared to all groups (P>0.01).
Table 2. New Bone Area (group means±SD, mm2, n=10)
Group 2 weeks 8 weeks
MBCP 0.8 ± 0.2 2.1 ± 1.1*
rhBMP-2/MBCP 3.9 ± 0.7¶ 5.8 ± 2.4*¶
  *: Statistically significant difference compared to 2 weeks (p<0.01).
  ¶: Statistically significant difference compared to MBCP group (p<0.01).
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degradation of the biomaterial. Macropores ≥100μm 
act as a scaffold for bone cells, thereby allowing cen-
tripetal bone ingrowth23). The newly formed bone is in 
direct contact with the biomaterial surface, making 
this biomaterial osteoconductive. In addition to the 
well-documented osteoconductive effect, the os-
teoinductive effect of the MBCP is recommended for 
use as an alternative or additive to autogenous bone 
for orthopedics, traumatology, odontology and dental 
applications24,25). 
The porous structure, low resorption rate, favorable 
osteoconductive and bioactive properties of MBCP can 
be utilized by the rhBMPs carrier. The porous struc-
ture of MBCP can be retained, allow the slow release 
of rhBMPs, and provide the appropriate scaffold to 
allow cells and newly formed tissues to migrate into 
it. In clinical aspects, the MBCP block is a very in-
teresting biomaterial for use as a carrier for BMPs 
because it can be manipulated easily to make the in-
tended shape. However, there have been few studies 
on its use as a carrier for BMPs29,30).
In this study, new bone formation in the macro-
pores of the block was evident in the rhBMP-2/MBCP 
sites. The new bone area was greater at 8 weeks than 
at 2 weeks. The quantity of the new bone had in-
creased further with the more advanced stage of 
remodeling. In addition, the total augmented area was 
stable during the healing period. In subcutaneous tis-
sue of rats, this favorable results confirmed that the 
MBCP block is a good carrier system for tissue en-
gineering using rhBMPs. 
In conclusion, the use of the block type of MBCP as 
a carrier for rhBMP-2 is effective in inducing new 
bone formation. The new bone induced by the 
rhBMPs/MBCP block system was stable during the ob-
served healing period. These results suggest that the 
MBCP block system can be used as a carrier system 
for tissue engineering using rhBMPs 
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